APRE logo

APRE
Aprea Therapeutics Inc

8,282
Mkt Cap
$8.01M
Volume
89,098.00
52W High
$2.22
52W Low
$0.548
PE Ratio
-0.35
APRE Fundamentals
Price
$0.711
Prev Close
$0.6992
Open
$0.6988
50D MA
$0.752
Beta
0.72
Avg. Volume
552,075.31
EPS (Annual)
-$1.93
P/B
0.46
Rev/Employee
$35,719.88
$8.29
Loading...
Loading...
News
all
press releases
Aprea Therapeutics Stock Rises After Company Reports Second Unconfirmed Case Of Tumor Reduction In Trial
The company reported a second unconfirmed partial response in a patient with advanced endometrial cancer being treated at the 220 mg dose level.
Stocktwits·2mo ago
News Placeholder
More News
News Placeholder
Aprea Therapeutics Advanced Cancer Trial Shows Promising Results, Stock Soars
Aprea Therapeutics shares rise after promising Phase 1 trial results with APR-1051 in cancer treatment.read more...
Benzinga·2mo ago
News Placeholder
New Strong Sell Stocks for January 19th
APRE, NFE and CZR have been added to the Zacks Rank #5 (Strong Sell) List on January 19, 2026.
Zacks·3mo ago
News Placeholder
New Strong Sell Stocks for Jan. 14
APRE, CULP and PSKY have been added to the Zacks Rank #5 (Strong Sell) List on Jan.13, 2026.
Zacks·3mo ago
News Placeholder
Marc Duey Acquires 21,459 Shares of Aprea Therapeutics (NASDAQ:APRE) Stock
Aprea Therapeutics, Inc. (NASDAQ:APRE - Get Free Report) Director Marc Duey purchased 21,459 shares of the firm's stock in a transaction on Wednesday, December 10th. The shares were acquired at an...
MarketBeat·4mo ago
<
...
1
>

Latest APRE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.